CMTM4 and neoplasm: Since loss of CMTM4 reversed the suppressive tumor immune environment by reducing PMN-MDSC infiltration (Fig. 6D–F), we reasoned that immune checkpoint blockade, such as PD-L1 antibody treatment, can further promote T cell activation in a less suppressive environment when combined with CMTM4 KD, and eventually inhibit tumor growth.